CRISPR Therapeutics files $600M ATM offering through Jefferies

CRISPR Therapeutics AG

Filed prospectus supplement to sell up to $600M of common shares at-the-market.
Offering uses existing shelf registration (Form S-3ASR filed Aug 5, 2024).
Jefferies LLC acts as sole sales agent; shares sold at company's discretion.
Legal opinion of Walder Wyss AG filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.